这是一项跨国、多中心、前瞻性及回顾性、观察性、队列研究，对象为骨髓增殖性肿瘤患者。
适应症：Myeloproliferative Neoplasm、Polycythemia Vera、Essential Thrombocythemia、Post-polycythemia Vera Myelofibrosis、Post-essential Thrombocythemia Myelofibrosis、Primary Myelofibrosis、Primary Myelofibrosis, Prefibrotic Stage、Primary Myelofibrosis, Fibrotic Stage
入组条件
纳入标准
- Age ≥ 18 years old at the time of diagnosis of MPN.
- Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
- Polycythaemia vera
- Essential thrombocythemia
- Primary myelofibrosis, pre-fibrotic/early stage
- Primary myelofibrosis, overt fibrotic stage
- Post-polycythaemia vera myelofibrosis
- Post-essential thrombocythaemia myelofibrosis
- MPN-unclassifiable
- All subjects need to provide informed consent.
排除标准
- A subject will not be eligible if he/she meets any of the following criteria:
- \. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。